Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries.
Journal
Annals of internal medicine
ISSN: 1539-3704
Titre abrégé: Ann Intern Med
Pays: United States
ID NLM: 0372351
Informations de publication
Date de publication:
15 10 2019
15 10 2019
Historique:
pubmed:
10
9
2019
medline:
17
6
2020
entrez:
10
9
2019
Statut:
ppublish
Résumé
The large observed variability in hemophilia prevalence prevents robust estimation of burden of disease. To estimate the prevalence and prevalence at birth of hemophilia and the associated life expectancy disadvantage. Random-effects meta-analysis of registry data. Australia, Canada, France, Italy, New Zealand, and the United Kingdom. Male patients with hemophilia A or B. Prevalence of hemophilia as a proportion of cases to the male population, prevalence of hemophilia at birth as a proportion of cases to live male births by year of birth, life expectancy disadvantage as a 1 - ratio of prevalence to prevalence at birth, and expected number of patients worldwide based on prevalence in high-income countries and prevalence at birth. Prevalence (per 100 000 males) is 17.1 cases for all severities of hemophilia A, 6.0 cases for severe hemophilia A, 3.8 cases for all severities of hemophilia B, and 1.1 cases for severe hemophilia B. Prevalence at birth (per 100 000 males) is 24.6 cases for all severities of hemophilia A, 9.5 cases for severe hemophilia A, 5.0 cases for all severities of hemophilia B, and 1.5 cases for severe hemophilia B. The life expectancy disadvantage for high-income countries is 30% for hemophilia A, 37% for severe hemophilia A, 24% for hemophilia B, and 27% for severe hemophilia B. The expected number of patients with hemophilia worldwide is 1 125 000, of whom 418 000 should have severe hemophilia. Details were insufficient to adjust for comorbid conditions and ethnicity. The prevalence of hemophilia is higher than previously estimated. Patients with hemophilia still have a life expectancy disadvantage. Establishing prevalence at birth is a milestone toward assessing years of life lost, years of life with disability, and burden of disease. None.
Sections du résumé
Background
The large observed variability in hemophilia prevalence prevents robust estimation of burden of disease.
Objective
To estimate the prevalence and prevalence at birth of hemophilia and the associated life expectancy disadvantage.
Design
Random-effects meta-analysis of registry data.
Setting
Australia, Canada, France, Italy, New Zealand, and the United Kingdom.
Participants
Male patients with hemophilia A or B.
Measurements
Prevalence of hemophilia as a proportion of cases to the male population, prevalence of hemophilia at birth as a proportion of cases to live male births by year of birth, life expectancy disadvantage as a 1 - ratio of prevalence to prevalence at birth, and expected number of patients worldwide based on prevalence in high-income countries and prevalence at birth.
Results
Prevalence (per 100 000 males) is 17.1 cases for all severities of hemophilia A, 6.0 cases for severe hemophilia A, 3.8 cases for all severities of hemophilia B, and 1.1 cases for severe hemophilia B. Prevalence at birth (per 100 000 males) is 24.6 cases for all severities of hemophilia A, 9.5 cases for severe hemophilia A, 5.0 cases for all severities of hemophilia B, and 1.5 cases for severe hemophilia B. The life expectancy disadvantage for high-income countries is 30% for hemophilia A, 37% for severe hemophilia A, 24% for hemophilia B, and 27% for severe hemophilia B. The expected number of patients with hemophilia worldwide is 1 125 000, of whom 418 000 should have severe hemophilia.
Limitation
Details were insufficient to adjust for comorbid conditions and ethnicity.
Conclusion
The prevalence of hemophilia is higher than previously estimated. Patients with hemophilia still have a life expectancy disadvantage. Establishing prevalence at birth is a milestone toward assessing years of life lost, years of life with disability, and burden of disease.
Primary Funding Source
None.
Identifiants
pubmed: 31499529
pii: 2749729
doi: 10.7326/M19-1208
doi:
Types de publication
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
540-546Investigateurs
Jeffrey S Stonebraker
(JS)
Alfonso Iorio
(A)
Vanessa Byams
(V)
Magdy El-Ekiaby
(M)
Michael Makris
(M)
Jamie O’Hara
(J)
Hervé Chambost
(H)
Glenn F Pierce
(GF)
Alain Weill
(A)
Commentaires et corrections
Type : CommentIn